A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes
Status:
Completed
Trial end date:
2020-08-23
Target enrollment:
Participant gender:
Summary
This study looks at the safety and tolerability of the new medicine NNC0268-0965 (referred to
as insulin 965), its concentration in the blood and its effect on the blood sugar for the
treatment of diabetes. The study will test how insulin 965 is tolerated by the body, how it
is taken up in the blood, how long it stays there and how the blood sugar is lowered.
Participants will either get the new insulin 965 or the already marketed insulin glargine
U100 (Lantus®) - which treatment is decided by chance. Participants will get six injections
(one per day) of either insulin 965 or insulin glargine U100 under the skin of the left
thigh. The study will last for about 5 weeks. Participants will have 6 clinic visits with the
study doctor. Participants can only be in the study if the study doctor thinks that there are
no risks for their health. Women can only take part in the study if they can't have children.